you, and morning, Tina, good everyone. Thank
our range We adjusted with well. Rheumatology of by growth driven KRYSTEXXA the strong up and increased as full-year EBITDA of generated another guidance XX%. segment XX%, quarter midpoint Orphan We our
driving EBITDA adjusted digits launch This business. investment significant the significant midpoint. the our growth our year-over-year underscores at are double would Excluding teprotumumab from we underlying be expansion margin
milestones submitted We March Review We quarter. key PDUFA designation BLA reached teprotumumab several received during for third Priority with date. the X, and the XXXX our
additional significant medical in trial at our several also pre-launch progress data present making while activities. meetings X Phase We
With strong continued KRYSTEXXA, KRYSTEXXA the in our to PROTECT to trial with performance, evaluate placebo-controlled quarter’s the we and addition registration in enrolling patients commercial gout. kidney trial of uncontrolled use transplant MIRROR launched
early have data label We MIRROR from in trial pilot to also expect XXXX. open our
our debt with With and our the stronger with reduced of structure net Pasternak peers. of We as gross to Andy has as on sheet invest continue our Sue times us to a and join us flexibility provides line and Board Company. new our leverage in our the brought having Director growth Also, we Mahony of a $XXX Chief been profitable as biopharma X.X well as never position welcome in capital the balance million, Officer. Business cash
the I’m which gender a organization, ethnic pay where we conducted which for that findings are showed also to best recent throughout analysis pleased critical Horizon talent. demonstrates marketplace Aon behalf, equity on report today’s and the in is of competing our
top we studied This In Horizon. in the this has all with at aligns Aon quality we of in five ranked and value fact, with companies the regard. diversity place
XXXX talent. recruit our of further XXX underscores which top consecutive medium sized out ranked the helps for fourth other selected year to Fortune our Xth Best We Medium also of Workplaces. us by employees We’re as one commitment and companies,
results, third I’ll now recap quarter our well discuss our as as teprotumumab activities. financial prelaunch
net Orphan our sales EBITDA XX% million adjusted sales. total and quarterly third $XXX We of sales of of Rheumatology net represent net generated million. quarter $XXX and of million $XXX approximately
patients both digits increased improved orphan PROCYSBI Demand remains across our RAVICTI combined Average for ACTIMMUNE, driven by quarter. shipping mid the medicines and single growth. strong, for compliance and patient
lower indications and younger, PROCYSBI many With the on older. starting treatment will patients are RAVICTI, increase new which as doses, for expanded they grow
Our and of support orphan journey. throughout driven treatment their patient growth ongoing by patients identification, is diagnosis strategy
earlier, performance growth with again driver expect is full-year on net by driven Based the we than than strong quarter, throughout of XX%, As more XX%. net I more sales growth said third performance major the XX%. KRYSTEXXA primarily increasing KRYSTEXXA vial sales now of
last We months. have new over accounts number of significant XX the opened a
the existing We’re Today, particularly physician or this up significant use excited of of nine with a patients. existing in XX% of practices the last remaining. is KRYSTEXXA accounts where to growth from deal growth year opportunity vial months year, see one two great majority coming first to compared with
is goal transform regularly gout, these uncontrolled into one of we KRYSTEXXA benefit treating with chronic Excellence, many they’re and help term practices two-patient Our as from to gout where or Centers more patients what KRYSTEXXA. patients with their
education the positive to through KRYSTEXXA this and continued patients. doing We’re clinical experience provides
We and year KRYSTEXXA. I’ll therefore on physicians this in of of practice to in acid levels uric had better identify the one this burden, predict share elevate to patient practice an systemic only practice understand monitoring need effectively treat, enabling of the them as response. last example importance urgency more Ohio on well at held the patients where impact them as to multi-physician urate educated help
be out efforts successful. These to turned very have
success to defromed the And so more patients with were of helped disease is At within to new from KRYSTEXXA. in that a patients gout. One, nephrologists. identification with associated So, treating hands this chronic note patient this had by of far was first practice. the tophi XX XX his uncontrolled his patients practice the KRYSTEXXA. example years old, was He patients lead about have referred the responder these their that this year, severe interesting his begun complete XX
from space. understand accelerating KRYSTEXXA our see PROTECT uptake our to start further demonstrate of to continue the and expect We nephrologists commitment nephrology in to the trial
U.S. of $XXX towards KRYSTEXXA sales With fundamentals, a than continued by annual peak $XXX business sales on are quarter, growth our target KRYSTEXXA strong million well nearly million. and driven volume net net we track more
trajectory of strategy, is success change by to which commercial our the factors. ability driven three underscores KRYSTEXXA’s Our growth
infrastructure First, physicians in educate and analyses the data clinical dynamics, studies right market the understanding team to the clinical invest and disease medicine, improve and to disease our its treatment. deeply and of and and required building the support understanding spend patients, the the the both,
same We principles and disease. to are teprotumumab applying autoimmune vision eye is thyroid the disease, which and progressive serious, threatening a
TED Today, deal no a there advocacy and involved is therefore, for including many patient been groups We’ve patients communities no from healthcare TED, and treatment learning approved medicine providers. defined with great groups, path. the
deeper treatment includes understanding of much entire patients which over serve needs, for their beyond. have support We journey their we how diagnosis to and can from
highly prescribed in relatively a for course the six-month biologic of hopeful that TED. therapy may a efficacious of short are represent care first-in-class We dramatic advance
community, support to treatment and the We’re making medicine. will to advance significant and educate able standard ensuring as success of patients prepare as And be well who is the investments teprotumumab critical to access market. need care the with our this
now some I’ll progress. through of walk our
teprotumumab specialists team XXX-person medical Our educators, sales and liaisons. is patient specialists, now of includes place, care representatives, reimbursement site in
are endocrinologists. Our called majority as physician prelaunch total. and X,XXX ophthalmologists well our have such meeting neuro-ophthalmologists been our efforts, our with vast of date, on targets. sales which surgeons including targets, X,XXX about mainly representatives force our as our as physician These of oculoplastic in top-tier is sub-specialties and the sales majority To as their the part targets, of are
Turning outreach. our to
the see. information that on gathering We of number TED they patients are
discussed, XX,XXX TED and previously physicians XX,XXX eligible the has active these As estimate teprotumumab we’ve initial similar. for from we confirmed each are that are to patients feedback year targeted numbers
amount a an that teprotumumab therapy, is addition, network. significant referral infusion or learned infused In about we’ve infusion capabilities given their
have patients for centers how experience While why infusions. many physicians TED This endocrinologists know works. to this infusion, important a educated their ophthalmologists refer with is to because outreach many where be This and need strategy. others of they critical our would is part infusion is process minimal on
network, ensure options have Our a appropriate there to patients goal site for successfully to care infusion is the their physicians so is treatment. will an that viable to treating refer of comprehensive
site their as the XXX service major the operating educate well have nearly center of specialists in to with standing procedures of met Over TED. our months, infusion about few as capabilities understand the care staff infusion providers last
We before they doing, with positive they very us Many have impressed groundwork have see something told received we’re how feedback. launch. really are the
access An patients. also support strategy for effective TED will reimbursement
dialog care educate to managed on from feedback team these the been and with payers positive. initial TED, them Our has also been in has interactions
the is compelling not the primary patients therapy XX.X% data, our particularly to short therapy only but X is with what responded When of majority meeting reviewing the in Phase program. endpoint teprotumumab’s clinical Phase trial course in the of that X our
can temporary approval, In days. to approved build or code addition, manual, The are newly reimbursement infused case-by-case will review a take codes, that process between drug usage. for temporary teprotumumab and all requiring therapies under needed which coding XX like and miscellaneous is XX reimbursement receive
XXXX, the that and for J will we is will be who March XXXX, is reimbursement providers for the teprotumumab end of more process If efficient when care. by approved in eligible permanent become January of code
teprotumumab progress invested the great with been in efforts, so significantly build interaction and treatment to to in far medical is e ophthalmologists at understanding presence has disease. and presenting have TED building the path, important referral access patient endocrinologists developing treatment. and successful the ensure establishing making infrastructure networks a our We’re Equally and urgency this identify these tremendous. clinical of seven significant year. infrequent in a Response have to meetings data greater
remotely Ophthalmic Plastic with Surgery or X,XXX and people for attending. was presentation of Our about October ASOPRS, standing American Reconstructive Society
We’re ASOPRS, symposia. conferences at our X,XXX American the XXX-plus Association Academy seeing at strong we attending and our attend, Ophthalmology with physicians TED the more The than visiting American physicians booth Meeting very Meeting interest with of Thyroid
for American oral week. meeting, our an Furthermore, selected of presentation the next was Rheumatology data at College
may to to infusion excitement TED prepared Given treating launch. is tremendous with for are generating. rheumatologists’ All biologic referral comfort now be physicians. for There experience a is this a and a major be we reason successful points option driving prelaunch they work key significant teprotumumab medicines, the significant
the many with lives for excited living people possibility TED. changing of of truly We’re
Shao-Lee to I activities. will provide over our it now development update an to turn on
